Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene (Q35681816)
Jump to navigation
Jump to search
scientific article published on 10 May 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene |
scientific article published on 10 May 2011 |
Statements
1 reference
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene (English)
1 reference
Marc Ladanyi
1 reference
William Pao
1 reference
Mark G Kris
1 reference
Valerie Rusch
1 reference
Ronglai Shen
1 reference
Maureen Zakowski
1 reference
Robert T Heelan
1 reference
Jamie E Chaft
1 reference
Bhuvanesh Singh
1 reference
Christopher G Azzoli
1 reference
Naiyer A Rizvi
1 reference
Bernard Park
1 reference
Vincent A Miller
1 reference
Lee M Krug
1 reference
Manjit Bains
1 reference
Robert Downey
1 reference
Raja Flores
1 reference
1 reference
1 reference
Identifiers
1 reference